88829-82-7

Basic information

• Product Name: 1-BOC-1,8-DIAMINOOCTANE
• Synonyms: N-t-Butyloxycarbonyl-1,8-diaminooctane;tert-Butyl (8-aminooct-1-yl)carbamate;Octane-1,8-diamine, N-BOC protected 95%;tert-Butyl (8-aminooct-1-yl)carbamate, 1,8-Diaminooctane, N-BOC protected;N-tert-Butoxycarbonyl-1,8-octanediaMine;Carbamic acid,N-(8-aminooctyl)-, 1,1-dimethylethyl ester;1-BOC-1,8-DIAMINOOCTANE;TERT-BUTYL 8-AMINOOCTYLCARBAMATE
• CAS NO: 88829-82-7
• Molecular Formula: C₁₃H₂₈N₂O₂
• Molecular Weight: 244.37
• Product Categories: pharmacetical
• Mol File: 88829-82-7.mol
• Article Data: 37

Chemical Properties

• Boiling Point: 356.3 °C at 760 mmHg
• Flash Point: 169.3 °C
• Appearance: /
• Density: 0.942 g/cm³
• Vapor Pressure: 2.96E-05mmHg at 25°C
• Refractive Index: 1.461
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: 1-BOC-1,8-DIAMINOOCTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-1,8-DIAMINOOCTANE(88829-82-7)
• EPA Substance Registry System: 1-BOC-1,8-DIAMINOOCTANE(88829-82-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 88829-82-7(Hazardous Substances Data)

Usage

Description

tert-butyl (8-aminooctyl)carbamate can be used as a PROTAC linker in the synthesis of PROTACs. tert-butyl (8-aminooctyl)carbamate is an alkane chain with terminal amine and Boc-protected amino groups. Amine group is reactive with carboxylic acids, activated NHS esters, carbonyls (ketone, aldehyde) etc. The Boc group can be deprotected under mild acidic conditions to form the free amine.

InChI:InChI=1/C13H28N2O2/c1-13(2,3)17-12(16)15-11-9-7-5-4-6-8-10-14/h4-11,14H2,1-3H3,(H,15,16)

Upstream product

• 142356-35-2 8-amino>octyl bromide 
• 144183-31-3 N-(8-hydroxyoctyl)carbamic acid tert-butyl ester 
• 57395-46-7 8-azidooctan-1-ol 
• 23144-52-7 8-chlorooctan-1-ol 
• 19008-71-0 8-aminooctan-1-ol 
• 373-44-4 1,8-diaminooctan 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 6627-89-0 tert-butyl phenyl carbonate 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 556065-55-5 N-(8-aminooctyl)-2,2,2-trifluoroacetamide 
• 556065-56-6 tert-butyl N-{8-[(trifluoroacetyl)amino]octyl}carbamate 
• 82409-00-5 N,N'-bis(t-butoxycarbonyl)-1,8-octanediamine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 395063-10-2 Fmoc-Tyr(O-Pic)-NH-(CH₂)8-NH-Boc 
• 556065-57-7 4-[(1E)-3-({8-[(tert-butoxycarbonyl)amino]octyl}amino)-3-oxoprop-1-enyl]phenyl acetate 
• 678188-75-5 tert-butyl [8-(1-phenethylpiperidin-4-ylamino)octyl]carbamate 
• 395063-14-6 (8-{2-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexanecarbonyl]-amino}-3-[4-(pyridin-4-ylmethoxy)-phenyl]-propionylamino}-octyl)-carbamic acid tert-butyl ester 
• 1026572-83-7 H-Tyr(O-Pic)-NH-(CH₂)8-NH-Boc 
• 678188-89-1 C₃₅H₅₉N₅O₅ 
• 678188-85-7 N-(8-amino-octyl)-N-(1-phenethyl-piperidin-4-yl)-propionamide 
• 678188-80-2 tert-butyl {8-[(1-phenethylpiperidin-4-yl)propionylamino]octyl}carbamate 
• 678188-89-1 N-[8-(N²,N³-bis(tert-butoxycarbonyl)guanidino)octyl]-N-(1-phenethylpiperidin-4-yl)propanamide 
• 1315482-50-8 C₂₉H₃₈F₆N₄O₄S 
• 1315482-48-4 C₃₄H₄₆F₆N₄O₆S 
• 1315482-49-5 C₁₇H₂₂F₆N₂O 
• 1315482-47-3 C₂₂H₃₀F₆N₂O₃ 

Relevant articles and documents

Construction of dye-stapled Quenchbodies by photochemical crosslinking to antibody nucleotide-binding sites

We successfully converted an antibody single-chain variable fragment and a full-sized antibody to Quenchbodies, which are a type of powerful fluorescent immunosensor, through ultraviolet-based photochemical crosslinking of an indole-3-butyric acid-conjugated fluorescent dye to the nucleotide-binding sites near the antigen-binding sites.

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma

Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.

Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs

The human tyrosinase is the most prominent therapeutic target for pigmentary skin disorders. However, the overwhelming majority efforts have been devoted to search mushroom tyrosinase inhibitors, which show poor inhibitory activity on human tyrosinase and certain side effects that cause skin damage in practical application. Herein, a series of degraders that directly targeted human tyrosinase was firstly designed and synthesized based on newly developed PROTAC technology. The best PROTAC TD9 induced human tyrosinase degradation obviously in dose and time-dependent manner, and its mechanism of inducing tyrosinase degradation has also been clearly demonstrated. Besides, encouraging results that low-toxicity PROTAC TD9 was applied to reduce zebrafish melanin synthesis have been obtained, highlighting the potential to treatment of tyrosinase-related disorders. Moreover, this work has innovatively expanded the application scope of PROTAC technology and laid a solid foundation for further development of novel drugs treating pigmentary skin disorders.

Target protein degradation inducing compound, preparation method thereof and pharmaceutical composition for preventing or treating targeted protein related diseases containing the same as an active ingredient

The present invention relates to a degraducer for inducing the decomposition of target protein, a producing method thereof, and a pharmaceutical composition for preventing or treating target protein-related diseases by containing the degraducer as an active ingredient. A novel compound represented by chemical formula 1, ULB-L-PTM, by the present invention, as a degraducer compound inducing the decomposition of target protein using cereblon E3 ubiquitin ligase, is able to significantly achieve a target protein degradation-inducing activity with an excellent binding activity of a cereblon E3 ubiquitin ligase binder thereby, being able to achieve an excellent protein degradation activity by targeting protein or polypeptide related to various diseases. The bromodomain-containing pharmaceutical composition for preventing or treating protein-related diseases or conditions contains the novel compound represented by chemical formula 1 as an active ingredient and has a useful effect of providing a health functional food composition for prevention or improvement.(AA) Example 22 (nM, 24h)COPYRIGHT KIPO 2020